Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep M Llibre

Showing results (91-100 of 162) with videos related to

Pageof 17
Sort By:
AIDS (London, England)|November 5, 2013
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infectionMaria C Puertas, Marta Massanella, Josep M Llibre, et al.
The Journal of Antimicrobial Chemotherapy|October 29, 2022
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimensJoaquin Burgos, Sergio Moreno-Fornés, Juliana Reyes-Urueña, et al.
Journal of the International AIDS Society|November 15, 2014
Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patientsDaniel Podzamczer, Jhon Fredy Rojas, Isabel Neves, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|October 5, 2010
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]Josep M Llibre, Antonio Antela, José Ramón Arribas, et al.
Open Forum Infectious Diseases|January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO StudyRuolan Wang, Mark Underwood, Josep M Llibre, et al.
Antiviral Therapy|February 1, 2012
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week studyJosep M Llibre, Maria J Buzón, Marta Massanella, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretroviralsArkaitz Imaz, Josep M Llibre, Marta Mora, et al.
Antiviral Therapy|June 26, 2014
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravirJosé L Blanco, Ana Gonzalez-Cordón, Josep M Llibre, et al.
Nature Medicine|March 16, 2010
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsMaria J Buzón, Marta Massanella, Josep M Llibre, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patientsAnna Bonjoch, Roger Paredes, Pere Domingo, et al.
Pageof 17

Showing results (91-100 of 162) with videos related to

Sort By:
Pageof 17
AIDS (London, England)|November 5, 2013
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infectionMaria C Puertas, Marta Massanella, Josep M Llibre, et al.
The Journal of Antimicrobial Chemotherapy|October 29, 2022
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimensJoaquin Burgos, Sergio Moreno-Fornés, Juliana Reyes-Urueña, et al.
Journal of the International AIDS Society|November 15, 2014
Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patientsDaniel Podzamczer, Jhon Fredy Rojas, Isabel Neves, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|October 5, 2010
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]Josep M Llibre, Antonio Antela, José Ramón Arribas, et al.
Open Forum Infectious Diseases|January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO StudyRuolan Wang, Mark Underwood, Josep M Llibre, et al.
Antiviral Therapy|February 1, 2012
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week studyJosep M Llibre, Maria J Buzón, Marta Massanella, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2010
Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretroviralsArkaitz Imaz, Josep M Llibre, Marta Mora, et al.
Antiviral Therapy|June 26, 2014
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravirJosé L Blanco, Ana Gonzalez-Cordón, Josep M Llibre, et al.
Nature Medicine|March 16, 2010
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsMaria J Buzón, Marta Massanella, Josep M Llibre, et al.
AIDS Research and Human Retroviruses|April 21, 2006
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patientsAnna Bonjoch, Roger Paredes, Pere Domingo, et al.
Pageof 17